<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250622066221N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-08-18</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>A comparative study of the efficacy of piroxicam ampoule mesotherapy injection and  shockwave modality on the clinical manifestations of knee osteoarthritis patients</public_title>
      <acronym></acronym>
      <scientific_title>A comparative study of the efficacy of piroxicam ampoule mesotherapy injection and shockwave modality on the clinical manifestations of knee osteoarthritis patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-09-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/84355</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The random allocation method in this study will be the permuted block randomization with blocks of size four. In this method, "A" represents the individual receiving the intervention, and "B" represents the individual receiving the control. Considering blocks of four, the total number of possible permutations is six, which are: ABAB, BABA, AABB, BBAA, ABBA, and BAAB.
Then, using a table of random numbers and assigning codes from 0 to 9 to each permutation, a random list of 60 assignments is generated. This list includes 25 blocks of four (4 × 25 = 60, which corresponds to the total sample  size). The order of assigning each method to the study participants is then determined accordingly. For example, the permutations are assigned codes as follows: ABAB = 0, BABA = 1, AABB = 2, BBAA = 3, BAAB = 4, and ABBA = 5 to 9. Then, using a table of random numbers, a random starting point is selected, and 25 numbers are randomly chosen (either row-wise or column-wise). The permutation corresponding to each selected number is recorded. (The order of the permutations will be arranged from left to right.) This process determines the allocation of all 60 participants into the two groups, A and B, Blinding description: The  study is one sided blind
Clinical caregiver: to the person who is in charge of the care and follow-up  of patients how to complete the questionnaires ,this person has no knowledge of the type of patients intervention .</study_design>
      <phase>3</phase>
      <hc_freetext>Osteoarthritis of knee.</hc_freetext>
      <i_freetext>The first intervention group: Patients received subcutaneous injections containing a combination of 20 mg, 1 ml of piroxicam and 5 cc of lidocaine 2%, in acupuncture points ST34, ST35, SP9, BL 38, SP10, LR7  around the knee ,The angle of the needle when entering the skin should be 30-45 degrees, after 10 days, the injection will be done again (each Patient will receive two mesotherapy sessions).The second intervention group: Under treatment with shock wave modality, patients will receive 0.05 millijoules per square millimeter of total energy with 1000 pulses per week for 3 weeks..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ramin Ardeshiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam hosaein dormitory ,hadaiat street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134934748</zip>
        <telephone>+98 83 3835 3624</telephone>
        <email>ramin.ardeshiri@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sharareh roshanzamir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam hosaein dormitory , hedaiat street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134934748</zip>
        <telephone>+98 83 3835 3624</telephone>
        <email>Sharareh.roshanzamir@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Mild to moderate knee osteoarthritis</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Injections in or around the knee joint in the last three months .   Use of NSIAD in the last three days .History of cancer ,diabetes ,rheumatological disease and vascular collagen .Heat and redness in the knee ,History of knee injury ,History of knee Arthroplasty or other surgeries on the knee ,Presence of active Radiculopathy ,myopathy ,peripheral neuropathy ,Pregnancy or breastfeeding ,BMI&gt;42 ,Allergy to piroxicam and other NSAID ,Severe gastrointestinal ,cardiovascular ,liver and kidney disease ,Any serious systemic or local infection such as brucellosis , Patients who have other musculoskeletal complications which Causes lower limb pain like secondary arthritis ,Patients who do Not complete the informed consent form to participate in the Study .</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: Patients received subcutaneous injections containing a combination of 20 mg, 1 ml of piroxicam and 5 cc of lidocaine 2%, in acupuncture points ST34, ST35, SP9, BL 38, SP10, LR7  around the knee ,The angle of the needle when entering the skin should be 30-45 degrees, after 10 days, the injection will be done again (each Patient will receive two mesotherapy sessions).The second intervention group: Under treatment with shock wave modality, patients will receive 0.05 millijoules per square millimeter of total energy with 1000 pulses per week for 3 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Osteoarthritis of knee. Timepoint: Measurement of knee joint cartilage thickness and evaluation of knee effusion before immediately after and one month after injection of piroxicam ampoule and shockwave  modality. Method of measurement: Visual analog scale , western Ontario and Mc master universities arthritis index , Oxford knee scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Improve pain and function. Timepoint: Investigation of pain improvement and performance ten days and one   month after piroxicam mesotherapy injection and shockwave modality. Method of measurement: Visual analog scale , Western Ontario and Mc Master universities arthritis   index ,oxford  knee scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-08-17</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Emam hosaein dormitory hedaiat street Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
